Correlation between immune-related adverse events and efficacy in non-small cell lung cancer treated with nivolumab

ObjectivesPatients treated with nivolumab often experience its unique adverse events, called immune-related adverse events (irAEs). Regarding the mechanisms of immune-checkpoint inhibitors (ICIs), the occurrence of irAEs may also reflect antitumor responses. Here, we report the clinical correlation between irAEs and efficacy in NSCLC patients treated with nivolumab.Materials and methodsBetween December 2015 and February 2017, 38 advanced NSCLC...